Previous 10 | Next 10 |
2024-02-04 08:45:00 ET As Wall Street embarks on the first full week of February, a large number of companies are set to release their earnings reports, providing a crucial glimpse into their financial standing and future outlook. From industry leaders like The Walt Disney Company (...
2024-02-02 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif. , Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tu...
2024-02-01 12:10:01 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...
2024-02-01 10:13:39 ET More on Bristol-Myers Squibb, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disag...
2024-02-01 10:13:39 ET More on Bristol-Myers, Johnson & Johnson, etc. Pfizer Is Down 54% From Highs, Now Yields 6.1% Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree Wit...
2024-02-01 02:30:29 ET Summary While revenue growth is steady 2014-2026E, the share price is up nearly threefold. Buybacks minimized equity and raised debt, limiting future per-share gains. Low R&D investment amid biosimilar competition and market pressures. $307 targe...
2024-01-29 08:30:00 ET As dividend investors know, there's an upside to investing in a big pharmaceutical business like Amgen (NASDAQ: AMGN) for dividend income. It likely has the resources and proven capabilities that'll enable it to stick around, and remain profitable enough to pa...
2024-01-29 07:56:57 ET Summary Amgen has delivered a 647% total return since 2011 and maintained a solid 10.04% 5-Year Dividend Growth Rate. Amid short-term product decisions and sales variations driving down operational efficiency, Amgen's diverse portfolio, global expansion, and...
deCODE genetics: A sequence variant that increases risk of pregnancy loss Canada NewsWire REYKJAVIK, Iceland , Jan. 29, 2024 /CNW/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland , Denmark, and the USA ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...